Olsalazine - DrugBank

ID Pharmacology Interactions References Trials Economics Properties Spectra Taxonomy

Targets (2)

Targets (2)Biointeractions (1)

Identification

Name

Olsalazine

Accession Number

DB01250

Type

Small Molecule

Groups

Approved

Description

Olsalazine is an anti-inflammatory drug used in the treatment of Inflammatory Bowel Disease and Ulcerative Colitis. Olsalazine is a derivative of salicylic acid. Inactive by itself (it is a prodrug), it is converted by the bacteria in the colon to mesalamine. Mesalamine works as an anti-inflammatory agent in treating inflammatory diseases of the intestines.

Structure

MOL SDF PDB SMILES InChI

Synonyms

Dipentum

External IDs

Not Available

Product Ingredients

Ingredient	UNII	CAS	InChI Key	Details
Olsalazine sodium	Y7JEW0XG7I	6054-98-4	QQWFSVYVHLECFP-XBPUGJBTSA-L	Details

Approved Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Dipentum	Capsule, gelatin coated	250 mg/1	Oral	Meda Pharmaceuticals Ltd	2015-05-15	Not applicable	US
Dipentum	Capsule	250 mg	Oral	Atnahs Pharma Uk Limited	1995-12-31	Not applicable	Canada
Dipentum	Capsule, gelatin coated	250 mg/1	Oral	Carilion Materials Management	1990-07-31	Not applicable	US
Dipentum	Capsule, gelatin coated	250 mg/1	Oral	Alaven Pharmaceutical	1990-07-31	Not applicable	US

Approved Generic Prescription Products

Not Available

Approved Over the Counter Products

Not Available

Unapproved/Other Products

Not Available

International Brands

Not Available

Brand mixtures

Not Available

Categories

UNII

ULS5I8J03O

CAS number

15722-48-2

Weight

Average: 302.239
Monoisotopic: 302.053886062

Chemical Formula

C₁₄H₁₀N₂O₆

InChI Key

QQBDLJCYGRGAKP-FOCLMDBBSA-N

InChI

InChI=1S/C14H10N2O6/c17-11-3-1-7(5-9(11)13(19)20)15-16-8-2-4-12(18)10(6-8)14(21)22/h1-6,17-18H,(H,19,20)(H,21,22)/b16-15+

IUPAC Name

5-[(E)-2-(3-carboxy-4-hydroxyphenyl)diazen-1-yl]-2-hydroxybenzoic acid

SMILES

OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(O)C(=C1)C(O)=O

Pharmacology

Indication

For the treatment of Inflammatory Bowel Disease and Ulcerative Colitis.

Structured Indications

Ulcerative Colitis (UC)

Pharmacodynamics

Olsalazine is an anti-inflammatory drug used in the treatment of Inflammatory Bowel Disease and Ulcerative Colitis. Olsalazine reduces the bowel inflammation, diarrhea (stool frequency), rectal bleeding, and abdominal pain. Like Balsalazide, Olsalazine is believed to deliver Mesalazine, or 5-aminosalicylic acid (5-ASA), past the small intestine, directly to the large intestine, which is that active site of disease in ulcerative colitis.

Mechanism of action

Orally administered olsalazine is converted to mesalamine which is thought to be the therapeutically active agent in the treatment of ulcerative colitis. The mechanism of action of mesalamine (and sulfasalazine) is unknown, but appears to be topical rather than systemic. Mucosal production of arachidonic acid (AA) metabolites, both through the cyclooxygenase pathways, i.e., prostanoids, and through the lipoxygenase pathways, i.e., leukotrienes (LTs) and hydroxyelcosatetraenoic acids (HETEs) is increased in patients with chronic inflammatory bowel disease, and it is possible that mesalamine diminishes inflammation by blocking cyclooxygenase and inhibiting prostaglandin (PG) production in the colon.

Target	Kind	Pharmacological action	Actions	Organism	UniProt ID
Thiopurine S-methyltransferase	Protein	yes	inhibitor	Human	P51580	details
Interferon gamma	Protein	yes	Not Available	Human	P01579	details

Absorption

After oral administration, olsalazine, has limited systemic bioavailability. 98-99% of the dose is converted to mesalamine (5-ASA) in the colon, which is absorbed slowly resulting in very high local concentrations in the colon.

Volume of distribution

Not Available

Protein binding

Olsalazine and olsalazine-S are more than 99% bound to plasma proteins. Mesalamine (5-ASA) is 74% bound to plasma proteins.

Metabolism

Most (98 to 99%) of an oral dose is rapidly converted into two molecules of 5-aminosalicylic acid (5-ASA) by colonic bacteria and the low prevailing redox potential found in this environment. The conversion of olsalazine to mesalamine in the colon is similar to that of sulfasalazine, which is converted into sulfapyridine and mesalamine. Approximately 0.1% of an oral dose of olsalazine is metabolized in the liver to olsalazine-O-sulfate (olsalazine-S)

Substrate	Enzymes	Product
Olsalazine	Not Available	Olsalazine-O-sulfate	Details

Route of elimination

Approximately 0.1% of an oral dose of olsalazine is metabolized in the liver to olsalazine-O-sulfate (olsalazine-S).The remaining 5-ASA is partially acetylated and is excreted in the feces.

Half life

Olsalazine has an elimination half-life of 0.9 hours, however, olsalazine-S has a half-life of 7 days.

Clearance

Not Available

Toxicity

Maximum single oral doses of 5g/kg in mice and rats and 2 g/kg in dogs were not lethal.

Affected organisms

Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
16-Bromoepiandrosterone	The risk or severity of adverse effects can be increased when Olsalazine is combined with 16-Bromoepiandrosterone.	Investigational
19-norandrostenedione	The risk or severity of adverse effects can be increased when Olsalazine is combined with 19-norandrostenedione.	Experimental, Illicit
5-androstenedione	The risk or severity of adverse effects can be increased when Olsalazine is combined with 5-androstenedione.	Experimental, Illicit
Abciximab	Olsalazine may increase the anticoagulant activities of Abciximab.	Approved
Acarbose	Olsalazine may increase the hypoglycemic activities of Acarbose.	Approved, Investigational
Acebutolol	Olsalazine may decrease the antihypertensive activities of Acebutolol.	Approved
Aceclofenac	Aceclofenac may increase the nephrotoxic activities of Olsalazine.	Approved
Acenocoumarol	Olsalazine may increase the anticoagulant activities of Acenocoumarol.	Approved
Acetazolamide	The risk or severity of adverse effects can be increased when Olsalazine is combined with Acetazolamide.	Approved, Vet Approved
Acetyldigitoxin	The serum concentration of Acetyldigitoxin can be decreased when it is combined with Olsalazine.	Approved
Acetylsalicylic acid	Acetylsalicylic acid may increase the nephrotoxic activities of Olsalazine.	Approved, Vet Approved
Aclarubicin	Olsalazine may decrease the excretion rate of Aclarubicin which could result in a higher serum level.	Investigational
Adapalene	Adapalene may increase the nephrotoxic activities of Olsalazine.	Approved
Albiglutide	Olsalazine may increase the hypoglycemic activities of Albiglutide.	Approved
Alclometasone	The risk or severity of adverse effects can be increased when Olsalazine is combined with Alclometasone.	Approved
Aldosterone	The risk or severity of adverse effects can be increased when Olsalazine is combined with Aldosterone.	Experimental
Alendronic acid	The risk or severity of adverse effects can be increased when Olsalazine is combined with Alendronic acid.	Approved
Aliskiren	Olsalazine may decrease the antihypertensive activities of Aliskiren.	Approved, Investigational
Alogliptin	Olsalazine may increase the hypoglycemic activities of Alogliptin.	Approved
Alprenolol	Olsalazine may decrease the antihypertensive activities of Alprenolol.	Approved, Withdrawn
Alprostadil	The therapeutic efficacy of Alprostadil can be decreased when used in combination with Olsalazine.	Approved, Investigational
Alteplase	The risk or severity of adverse effects can be increased when Olsalazine is combined with Alteplase.	Approved
Amcinonide	The risk or severity of adverse effects can be increased when Olsalazine is combined with Amcinonide.	Approved
Amikacin	Olsalazine may decrease the excretion rate of Amikacin which could result in a higher serum level.	Approved, Vet Approved
Amiloride	Olsalazine may decrease the antihypertensive activities of Amiloride.	Approved
Aminosalicylic Acid	Aminosalicylic Acid may increase the anticoagulant activities of Olsalazine.	Approved
Ammonium chloride	The serum concentration of Olsalazine can be increased when it is combined with Ammonium chloride.	Approved, Vet Approved
Amrubicin	Olsalazine may decrease the excretion rate of Amrubicin which could result in a higher serum level.	Approved, Investigational
Anagrelide	The risk or severity of adverse effects can be increased when Anagrelide is combined with Olsalazine.	Approved
Ancrod	Olsalazine may increase the anticoagulant activities of Ancrod.	Investigational
Andrographolide	HMPL-004 may increase the nephrotoxic activities of Olsalazine.	Investigational
Androstenedione	The risk or severity of adverse effects can be increased when Olsalazine is combined with 4-Androstenedione.	Experimental, Illicit
Anecortave	The risk or severity of adverse effects can be increased when Olsalazine is combined with Anecortave.	Investigational
Anisodamine	Anisodamine may increase the nephrotoxic activities of Olsalazine.	Investigational
Anistreplase	The risk or severity of adverse effects can be increased when Olsalazine is combined with Anistreplase.	Approved
Antipyrine	Antipyrine may increase the nephrotoxic activities of Olsalazine.	Approved
Antithrombin III human	Olsalazine may increase the anticoagulant activities of Antithrombin III human.	Approved
Apixaban	Olsalazine may increase the anticoagulant activities of Apixaban.	Approved
Apocynin	Acetovanillone may increase the nephrotoxic activities of Olsalazine.	Investigational
Apramycin	Olsalazine may decrease the excretion rate of Apramycin which could result in a higher serum level.	Experimental, Vet Approved
Apremilast	Apremilast may increase the nephrotoxic activities of Olsalazine.	Approved, Investigational
Arbekacin	Olsalazine may decrease the excretion rate of Arbekacin which could result in a higher serum level.	Approved
Ardeparin	The risk or severity of adverse effects can be increased when Olsalazine is combined with Ardeparin.	Approved, Withdrawn
Argatroban	Olsalazine may increase the anticoagulant activities of Argatroban.	Approved, Investigational
Arotinolol	Olsalazine may decrease the antihypertensive activities of Arotinolol.	Approved
Atenolol	Olsalazine may decrease the antihypertensive activities of Atenolol.	Approved
Azapropazone	Azapropazone may increase the nephrotoxic activities of Olsalazine.	Withdrawn
Azathioprine	The metabolism of Azathioprine can be decreased when combined with Olsalazine.	Approved
Azelastine	Azelastine may increase the nephrotoxic activities of Olsalazine.	Approved
Azilsartan medoxomil	The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Olsalazine.	Approved
Balsalazide	Balsalazide may increase the nephrotoxic activities of Olsalazine.	Approved, Investigational
Becaplermin	Olsalazine may increase the anticoagulant activities of Becaplermin.	Approved, Investigational
Beclomethasone dipropionate	The risk or severity of adverse effects can be increased when Olsalazine is combined with Beclomethasone dipropionate.	Approved, Investigational
Befunolol	Olsalazine may decrease the antihypertensive activities of Befunolol.	Experimental
Bemiparin	The risk or severity of adverse effects can be increased when Olsalazine is combined with Bemiparin.	Approved
Benazepril	The risk or severity of adverse effects can be increased when Benazepril is combined with Olsalazine.	Approved, Investigational
Bendroflumethiazide	The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Olsalazine.	Approved
Benoxaprofen	Benoxaprofen may increase the nephrotoxic activities of Olsalazine.	Withdrawn
Beraprost	The risk or severity of adverse effects can be increased when Beraprost is combined with Olsalazine.	Investigational
Betamethasone	The risk or severity of adverse effects can be increased when Olsalazine is combined with Betamethasone.	Approved, Vet Approved
Betaxolol	Olsalazine may decrease the antihypertensive activities of Betaxolol.	Approved
Betulinic Acid	Betulinic Acid may increase the nephrotoxic activities of Olsalazine.	Investigational
Bevantolol	Olsalazine may decrease the antihypertensive activities of Bevantolol.	Approved
Bimatoprost	The therapeutic efficacy of Bimatoprost can be decreased when used in combination with Olsalazine.	Approved, Investigational
Bisoprolol	Olsalazine may decrease the antihypertensive activities of Bisoprolol.	Approved
Bivalirudin	Olsalazine may increase the anticoagulant activities of Bivalirudin.	Approved, Investigational
Bopindolol	Olsalazine may decrease the antihypertensive activities of Bopindolol.	Approved
Brinzolamide	The risk or severity of adverse effects can be increased when Olsalazine is combined with Brinzolamide.	Approved
Bromfenac	Bromfenac may increase the nephrotoxic activities of Olsalazine.	Approved
Bromocriptine	Olsalazine may increase the hypoglycemic activities of Bromocriptine.	Approved, Investigational
Bucillamine	Bucillamine may increase the nephrotoxic activities of Olsalazine.	Investigational
Bucindolol	Olsalazine may decrease the antihypertensive activities of Bucindolol.	Investigational
Budesonide	The risk or severity of adverse effects can be increased when Olsalazine is combined with Budesonide.	Approved
Bufuralol	Olsalazine may decrease the antihypertensive activities of Bufuralol.	Experimental, Investigational
Bumetanide	Olsalazine may decrease the diuretic activities of Bumetanide.	Approved
Bupranolol	Olsalazine may decrease the antihypertensive activities of Bupranolol.	Approved
Butylphthalide	The risk or severity of adverse effects can be increased when Butylphthalide is combined with Olsalazine.	Investigational
Canagliflozin	Olsalazine may increase the hypoglycemic activities of Canagliflozin.	Approved
Candesartan	The risk or severity of adverse effects can be increased when Candesartan is combined with Olsalazine.	Approved
Candoxatril	The risk or severity of adverse effects can be increased when Candoxatril is combined with Olsalazine.	Experimental
Cangrelor	The risk or severity of adverse effects can be increased when Cangrelor is combined with Olsalazine.	Approved
Captopril	The risk or severity of adverse effects can be increased when Captopril is combined with Olsalazine.	Approved
Carboprost Tromethamine	The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Olsalazine.	Approved
Carprofen	Carprofen may increase the nephrotoxic activities of Olsalazine.	Approved, Vet Approved, Withdrawn
Carteolol	Olsalazine may decrease the antihypertensive activities of Carteolol.	Approved
Carvedilol	Olsalazine may decrease the antihypertensive activities of Carvedilol.	Approved, Investigational
Castanospermine	Castanospermine may increase the nephrotoxic activities of Olsalazine.	Experimental
Celecoxib	The risk or severity of adverse effects can be increased when Olsalazine is combined with Celecoxib.	Approved, Investigational
Celiprolol	Olsalazine may decrease the antihypertensive activities of Celiprolol.	Approved, Investigational
Certoparin	The risk or severity of adverse effects can be increased when Olsalazine is combined with Certoparin.	Approved
Chloroquine	Chloroquine may increase the nephrotoxic activities of Olsalazine.	Approved, Vet Approved
Chlorothiazide	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Olsalazine.	Approved, Vet Approved
Chlorpropamide	Olsalazine may increase the hypoglycemic activities of Chlorpropamide.	Approved
Chlorthalidone	The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Olsalazine.	Approved
Cholestyramine	Cholestyramine can cause a decrease in the absorption of Olsalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Choline magnesium trisalicylate	Trisalicylate-choline may increase the nephrotoxic activities of Olsalazine.	Approved
Ciclesonide	The risk or severity of adverse effects can be increased when Olsalazine is combined with Ciclesonide.	Approved, Investigational
Cilazapril	The risk or severity of adverse effects can be increased when Cilazapril is combined with Olsalazine.	Approved
Cilostazol	The risk or severity of adverse effects can be increased when Cilostazol is combined with Olsalazine.	Approved
Cinoxacin	Olsalazine may increase the neuroexcitatory activities of Cinoxacin.	Approved, Withdrawn
Ciprofloxacin	Olsalazine may increase the neuroexcitatory activities of Ciprofloxacin.	Approved, Investigational
Citric Acid	Olsalazine may increase the anticoagulant activities of Citric Acid.	Nutraceutical, Vet Approved
Clobetasol	The risk or severity of adverse effects can be increased when Olsalazine is combined with Clobetasol.	Investigational
Clobetasol propionate	The risk or severity of adverse effects can be increased when Olsalazine is combined with Clobetasol propionate.	Approved
Clocortolone	The risk or severity of adverse effects can be increased when Olsalazine is combined with Clocortolone.	Approved
Clodronic Acid	The risk or severity of adverse effects can be increased when Olsalazine is combined with Clodronate.	Approved, Investigational, Vet Approved
Clonixin	Clonixin may increase the nephrotoxic activities of Olsalazine.	Approved
Clopidogrel	The risk or severity of adverse effects can be increased when Clopidogrel is combined with Olsalazine.	Approved, Nutraceutical
Colesevelam	Colesevelam can cause a decrease in the absorption of Olsalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Colestipol	Colestipol can cause a decrease in the absorption of Olsalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Cortisone acetate	The risk or severity of adverse effects can be increased when Olsalazine is combined with Cortisone acetate.	Approved
Curcumin	Curcumin may increase the nephrotoxic activities of Olsalazine.	Investigational
Cyclosporine	Olsalazine may increase the nephrotoxic activities of Cyclosporine.	Approved, Investigational, Vet Approved
Dabigatran etexilate	Olsalazine may increase the anticoagulant activities of Dabigatran etexilate.	Approved
Dalteparin	The risk or severity of adverse effects can be increased when Olsalazine is combined with Dalteparin.	Approved
Dapagliflozin	Olsalazine may increase the hypoglycemic activities of Dapagliflozin.	Approved
Darexaban	Olsalazine may increase the anticoagulant activities of Ym150.	Investigational
Daunorubicin	Olsalazine may decrease the excretion rate of Daunorubicin which could result in a higher serum level.	Approved
Deferasirox	The risk or severity of adverse effects can be increased when Olsalazine is combined with Deferasirox.	Approved, Investigational
Defibrotide	The risk or severity of adverse effects can be increased when Defibrotide is combined with Olsalazine.	Approved, Investigational
Desirudin	Olsalazine may increase the anticoagulant activities of Desirudin.	Approved
Deslanoside	The serum concentration of Deslanoside can be decreased when it is combined with Olsalazine.	Approved
Desmopressin	The risk or severity of adverse effects can be increased when Olsalazine is combined with Desmopressin.	Approved
Desmoteplase	The risk or severity of adverse effects can be increased when Olsalazine is combined with Desmoteplase.	Investigational
Desoximetasone	The risk or severity of adverse effects can be increased when Olsalazine is combined with Desoximetasone.	Approved
Desoxycorticosterone Pivalate	The risk or severity of adverse effects can be increased when Olsalazine is combined with Desoxycorticosterone Pivalate.	Experimental, Vet Approved
Dexamethasone	The risk or severity of adverse effects can be increased when Olsalazine is combined with Dexamethasone.	Approved, Investigational, Vet Approved
Dexketoprofen	The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Olsalazine.	Approved
Dextran	Olsalazine may increase the anticoagulant activities of Dextran.	Approved, Vet Approved
Dextran 40	Olsalazine may increase the anticoagulant activities of Dextran 40.	Approved
Diclofenac	The risk or severity of adverse effects can be increased when Diclofenac is combined with Olsalazine.	Approved, Vet Approved
Diclofenac	Diclofenac may increase the nephrotoxic activities of Olsalazine.	Approved, Vet Approved
Diclofenamide	The risk or severity of adverse effects can be increased when Olsalazine is combined with Diclofenamide.	Approved
Dicoumarol	Olsalazine may increase the anticoagulant activities of Dicoumarol.	Approved
Diflorasone	The risk or severity of adverse effects can be increased when Olsalazine is combined with Diflorasone.	Approved
Diflunisal	Diflunisal may increase the nephrotoxic activities of Olsalazine.	Approved
Difluocortolone	The risk or severity of adverse effects can be increased when Olsalazine is combined with Difluocortolone.	Approved
Difluprednate	The risk or severity of adverse effects can be increased when Olsalazine is combined with Difluprednate.	Approved
Digitoxin	The serum concentration of Digitoxin can be decreased when it is combined with Olsalazine.	Approved
Digoxin	The serum concentration of Digoxin can be increased when it is combined with Olsalazine.	Approved
Diltiazem	Diltiazem may increase the anticoagulant activities of Olsalazine.	Approved
Dinoprost	The therapeutic efficacy of Dinoprost can be decreased when used in combination with Olsalazine.	Investigational
Dinoprost Tromethamine	The therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Olsalazine.	Approved, Vet Approved
Dinoprostone	The therapeutic efficacy of Dinoprostone can be decreased when used in combination with Olsalazine.	Approved
Dipyridamole	The risk or severity of adverse effects can be increased when Dipyridamole is combined with Olsalazine.	Approved
Disopyramide	Olsalazine may increase the hypoglycemic activities of Disopyramide.	Approved
Ditazole	The risk or severity of adverse effects can be increased when Olsalazine is combined with Ditazole.	Approved, Withdrawn
Dorzolamide	The risk or severity of adverse effects can be increased when Olsalazine is combined with Dorzolamide.	Approved
Doxorubicin	Olsalazine may decrease the excretion rate of Doxorubicin which could result in a higher serum level.	Approved, Investigational
Drospirenone	Olsalazine may increase the hyperkalemic activities of Drospirenone.	Approved
Drotrecogin alfa	The risk or severity of adverse effects can be increased when Olsalazine is combined with Drotrecogin alfa.	Approved, Investigational, Withdrawn
Droxicam	Droxicam may increase the nephrotoxic activities of Olsalazine.	Approved
Dulaglutide	Olsalazine may increase the hypoglycemic activities of Dulaglutide.	Approved
Duvelisib	Duvelisib may increase the nephrotoxic activities of Olsalazine.	Investigational
E-6201	E6201 may increase the nephrotoxic activities of Olsalazine.	Investigational
Ebselen	Ebselen may increase the nephrotoxic activities of Olsalazine.	Investigational
Edetic Acid	Olsalazine may increase the anticoagulant activities of Edetic Acid.	Approved, Vet Approved
Edoxaban	Olsalazine may increase the anticoagulant activities of Edoxaban.	Approved
Empagliflozin	Olsalazine may increase the hypoglycemic activities of Empagliflozin.	Approved
Enalapril	The risk or severity of adverse effects can be increased when Enalapril is combined with Olsalazine.	Approved, Vet Approved
Enalaprilat	The risk or severity of adverse effects can be increased when Enalaprilat is combined with Olsalazine.	Approved
Enoxacin	Olsalazine may increase the neuroexcitatory activities of Enoxacin.	Approved
Enoxaparin	The risk or severity of adverse effects can be increased when Olsalazine is combined with Enoxaparin.	Approved
Epinastine	The risk or severity of adverse effects can be increased when Epinastine is combined with Olsalazine.	Approved, Investigational
Epirizole	Epirizole may increase the nephrotoxic activities of Olsalazine.	Approved
Epirubicin	Olsalazine may decrease the excretion rate of Epirubicin which could result in a higher serum level.	Approved
Eplerenone	Olsalazine may decrease the antihypertensive activities of Eplerenone.	Approved
Epoprostenol	The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Olsalazine.	Approved
Eprosartan	The risk or severity of adverse effects can be increased when Eprosartan is combined with Olsalazine.	Approved
Eptifibatide	The risk or severity of adverse effects can be increased when Eptifibatide is combined with Olsalazine.	Approved, Investigational
Equilenin	The risk or severity of adverse effects can be increased when Olsalazine is combined with Equilenin.	Experimental
Equilin	The risk or severity of adverse effects can be increased when Olsalazine is combined with Equilin.	Approved
Esmolol	Olsalazine may decrease the antihypertensive activities of Esmolol.	Approved
Estrone	The risk or severity of adverse effects can be increased when Olsalazine is combined with Estrone.	Approved
Estrone sulfate	The risk or severity of adverse effects can be increased when Olsalazine is combined with Estrone sulfate.	Approved
Etacrynic acid	Olsalazine may decrease the diuretic activities of Etacrynic acid.	Approved
Etanercept	Etanercept may increase the nephrotoxic activities of Olsalazine.	Approved, Investigational
Ethoxzolamide	The risk or severity of adverse effects can be increased when Olsalazine is combined with Ethoxzolamide.	Withdrawn
Ethyl biscoumacetate	Olsalazine may increase the anticoagulant activities of Ethyl biscoumacetate.	Withdrawn
Etidronic acid	The risk or severity of adverse effects can be increased when Olsalazine is combined with Etidronic acid.	Approved
Etodolac	The risk or severity of adverse effects can be increased when Olsalazine is combined with Etodolac.	Approved, Investigational, Vet Approved
Etofenamate	Etofenamate may increase the nephrotoxic activities of Olsalazine.	Approved
Etoricoxib	The risk or severity of adverse effects can be increased when Olsalazine is combined with Etoricoxib.	Approved, Investigational
Exenatide	Olsalazine may increase the hypoglycemic activities of Exenatide.	Approved, Investigational
Fenbufen	Fenbufen may increase the nephrotoxic activities of Olsalazine.	Approved
Fenoprofen	Fenoprofen may increase the nephrotoxic activities of Olsalazine.	Approved
Fibrinolysin	The risk or severity of adverse effects can be increased when Olsalazine is combined with Plasmin.	Investigational
Fleroxacin	Olsalazine may increase the neuroexcitatory activities of Fleroxacin.	Approved
Floctafenine	The risk or severity of adverse effects can be increased when Floctafenine is combined with Olsalazine.	Approved, Withdrawn
Fludrocortisone	The risk or severity of adverse effects can be increased when Olsalazine is combined with Fludrocortisone.	Approved
Fluindione	Olsalazine may increase the anticoagulant activities of Fluindione.	Investigational
Flumequine	Olsalazine may increase the neuroexcitatory activities of Flumequine.	Withdrawn
Flumethasone	The risk or severity of adverse effects can be increased when Olsalazine is combined with Flumethasone.	Approved, Vet Approved
Flunisolide	The risk or severity of adverse effects can be increased when Olsalazine is combined with Flunisolide.	Approved, Investigational
Fluocinolone Acetonide	The risk or severity of adverse effects can be increased when Olsalazine is combined with Fluocinolone Acetonide.	Approved, Investigational, Vet Approved
Fluocinonide	The risk or severity of adverse effects can be increased when Olsalazine is combined with Fluocinonide.	Approved, Investigational
Fluocortolone	The risk or severity of adverse effects can be increased when Olsalazine is combined with Fluocortolone.	Approved, Withdrawn
Fluorometholone	The risk or severity of adverse effects can be increased when Olsalazine is combined with Fluorometholone.	Approved
Fluprednidene	The risk or severity of adverse effects can be increased when Olsalazine is combined with Fluprednidene.	Approved, Withdrawn
Flurandrenolide	The risk or severity of adverse effects can be increased when Olsalazine is combined with Flurandrenolide.	Approved
Flurbiprofen	Flurbiprofen may increase the nephrotoxic activities of Olsalazine.	Approved, Investigational
Fluticasone furoate	The risk or severity of adverse effects can be increased when Olsalazine is combined with Fluticasone furoate.	Approved
Fluticasone propionate	The risk or severity of adverse effects can be increased when Olsalazine is combined with Fluticasone Propionate.	Approved
Folic Acid	The therapeutic efficacy of Folic Acid can be decreased when used in combination with Olsalazine.	Approved, Nutraceutical, Vet Approved
Fondaparinux	Olsalazine may increase the anticoagulant activities of Fondaparinux.	Investigational
Fondaparinux sodium	Olsalazine may increase the anticoagulant activities of Fondaparinux sodium.	Approved, Investigational
Forasartan	The risk or severity of adverse effects can be increased when Forasartan is combined with Olsalazine.	Experimental
Formestane	The risk or severity of adverse effects can be increased when Olsalazine is combined with Formestane.	Approved, Investigational, Withdrawn
Fosinopril	The risk or severity of adverse effects can be increased when Fosinopril is combined with Olsalazine.	Approved
Framycetin	Olsalazine may decrease the excretion rate of Framycetin which could result in a higher serum level.	Approved
Furosemide	Olsalazine may decrease the diuretic activities of Furosemide.	Approved, Vet Approved
Gabexate	Olsalazine may increase the anticoagulant activities of Gabexate.	Investigational
Gatifloxacin	Olsalazine may increase the neuroexcitatory activities of Gatifloxacin.	Approved, Investigational
Gemeprost	The therapeutic efficacy of Gemeprost can be decreased when used in combination with Olsalazine.	Approved, Withdrawn
Gemifloxacin	Olsalazine may increase the neuroexcitatory activities of Gemifloxacin.	Approved, Investigational
Geneticin	Olsalazine may decrease the excretion rate of Geneticin which could result in a higher serum level.	Experimental
Gentamicin	Olsalazine may decrease the excretion rate of Gentamicin which could result in a higher serum level.	Approved, Vet Approved
GENTAMICIN C1A	Olsalazine may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.	Experimental
Ginkgo biloba	Ginkgo biloba may increase the anticoagulant activities of Olsalazine.	Approved, Nutraceutical
Gliclazide	Olsalazine may increase the hypoglycemic activities of Gliclazide.	Approved
Glimepiride	Olsalazine may increase the hypoglycemic activities of Glimepiride.	Approved
Glipizide	Olsalazine may increase the hypoglycemic activities of Glipizide.	Approved
Glyburide	Olsalazine may increase the hypoglycemic activities of Glyburide.	Approved
Grepafloxacin	Olsalazine may increase the neuroexcitatory activities of Grepafloxacin.	Withdrawn
Haloperidol	The risk or severity of adverse effects can be increased when Olsalazine is combined with Haloperidol.	Approved
HE3286	The risk or severity of adverse effects can be increased when Olsalazine is combined with HE3286.	Investigational
Heparin	The risk or severity of adverse effects can be increased when Olsalazine is combined with Heparin.	Approved, Investigational
Higenamine	Higenamine may increase the nephrotoxic activities of Olsalazine.	Investigational
Hyaluronidase	The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Olsalazine.	Approved, Investigational
Hydralazine	Olsalazine may decrease the antihypertensive activities of Hydralazine.	Approved
Hydrochlorothiazide	The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Olsalazine.	Approved, Vet Approved
Hydrocortisone	The risk or severity of adverse effects can be increased when Olsalazine is combined with Hydrocortisone.	Approved, Vet Approved
Hydroflumethiazide	The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Olsalazine.	Approved
Ibandronate	The risk or severity of adverse effects can be increased when Olsalazine is combined with Ibandronate.	Approved, Investigational
Ibudilast	The risk or severity of adverse effects can be increased when Ibudilast is combined with Olsalazine.	Approved, Investigational
Ibuprofen	Ibuprofen may increase the nephrotoxic activities of Olsalazine.	Approved
Ibuproxam	Ibuproxam may increase the nephrotoxic activities of Olsalazine.	Withdrawn
Icatibant	Icatibant may increase the nephrotoxic activities of Olsalazine.	Approved
Icosapent ethyl	The risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Olsalazine.	Approved, Nutraceutical
Idarubicin	Olsalazine may decrease the excretion rate of Idarubicin which could result in a higher serum level.	Approved
Ifenprodil	The risk or severity of adverse effects can be increased when Ifenprodil is combined with Olsalazine.	Approved, Withdrawn
Iloprost	The therapeutic efficacy of Iloprost can be decreased when used in combination with Olsalazine.	Approved, Investigational
Imidapril	The risk or severity of adverse effects can be increased when Imidapril is combined with Olsalazine.	Investigational
Indapamide	The therapeutic efficacy of Indapamide can be decreased when used in combination with Olsalazine.	Approved
Indenolol	Olsalazine may decrease the antihypertensive activities of Indenolol.	Withdrawn
Indobufen	The risk or severity of adverse effects can be increased when Olsalazine is combined with Indobufen.	Investigational
Indomethacin	Indomethacin may increase the nephrotoxic activities of Olsalazine.	Approved, Investigational
Indoprofen	Indoprofen may increase the nephrotoxic activities of Olsalazine.	Withdrawn
Insulin Aspart	Olsalazine may increase the hypoglycemic activities of Insulin Aspart.	Approved
Insulin Detemir	Olsalazine may increase the hypoglycemic activities of Insulin Detemir.	Approved
Insulin Glargine	Olsalazine may increase the hypoglycemic activities of Insulin Glargine.	Approved
Insulin Glulisine	Olsalazine may increase the hypoglycemic activities of Insulin Glulisine.	Approved
Insulin Human	Olsalazine may increase the hypoglycemic activities of Insulin Human.	Approved, Investigational
Insulin Lispro	Olsalazine may increase the hypoglycemic activities of Insulin Lispro.	Approved
Irbesartan	The risk or severity of adverse effects can be increased when Irbesartan is combined with Olsalazine.	Approved, Investigational
Isoxicam	Isoxicam may increase the nephrotoxic activities of Olsalazine.	Withdrawn
Kanamycin	Olsalazine may decrease the excretion rate of Kanamycin which could result in a higher serum level.	Approved, Vet Approved
Kebuzone	Kebuzone may increase the nephrotoxic activities of Olsalazine.	Experimental
Ketanserin	The risk or severity of adverse effects can be increased when Ketanserin is combined with Olsalazine.	Investigational
Ketoprofen	Ketoprofen may increase the nephrotoxic activities of Olsalazine.	Approved, Vet Approved
Ketorolac	The risk or severity of adverse effects can be increased when Ketorolac is combined with Olsalazine.	Approved
Ketorolac	Ketorolac may increase the nephrotoxic activities of Olsalazine.	Approved
Labetalol	Olsalazine may decrease the antihypertensive activities of Labetalol.	Approved
Landiolol	Olsalazine may decrease the antihypertensive activities of Aop200704.	Investigational
Lanreotide	Olsalazine may increase the hypoglycemic activities of Lanreotide.	Approved
Latanoprost	The therapeutic efficacy of Latanoprost can be decreased when used in combination with Olsalazine.	Approved, Investigational
Leflunomide	Leflunomide may increase the nephrotoxic activities of Olsalazine.	Approved, Investigational
Lepirudin	Olsalazine may increase the anticoagulant activities of Lepirudin.	Approved
Levobunolol	Olsalazine may decrease the antihypertensive activities of Levobunolol.	Approved
Levofloxacin	Olsalazine may increase the neuroexcitatory activities of Levofloxacin.	Approved, Investigational
Limaprost	The therapeutic efficacy of Limaprost can be decreased when used in combination with Olsalazine.	Approved
Liraglutide	Olsalazine may increase the hypoglycemic activities of Liraglutide.	Approved
Lisinopril	The risk or severity of adverse effects can be increased when Lisinopril is combined with Olsalazine.	Approved, Investigational
Lisofylline	Lisofylline may increase the nephrotoxic activities of Olsalazine.	Investigational
Lithium	The serum concentration of Lithium can be increased when it is combined with Olsalazine.	Approved
Lomefloxacin	Olsalazine may increase the neuroexcitatory activities of Lomefloxacin.	Approved
Lornoxicam	Lornoxicam may increase the nephrotoxic activities of Olsalazine.	Approved
Losartan	The risk or severity of adverse effects can be increased when Losartan is combined with Olsalazine.	Approved
Loxoprofen	Loxoprofen may increase the nephrotoxic activities of Olsalazine.	Approved
Lubiprostone	The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Olsalazine.	Approved, Investigational
Lumiracoxib	The risk or severity of adverse effects can be increased when Olsalazine is combined with Lumiracoxib.	Approved, Investigational
Magnesium salicylate	Magnesium salicylate may increase the nephrotoxic activities of Olsalazine.	Approved
Masoprocol	Masoprocol may increase the nephrotoxic activities of Olsalazine.	Approved
ME-609	The risk or severity of adverse effects can be increased when Olsalazine is combined with ME-609.	Investigational
Mecasermin	Olsalazine may increase the hypoglycemic activities of Mecasermin.	Approved, Investigational
Meclofenamic acid	Meclofenamic acid may increase the nephrotoxic activities of Olsalazine.	Approved, Vet Approved
Medrysone	The risk or severity of adverse effects can be increased when Olsalazine is combined with Medrysone.	Approved
Mefenamic acid	Mefenamic acid may increase the nephrotoxic activities of Olsalazine.	Approved
Meloxicam	Meloxicam may increase the nephrotoxic activities of Olsalazine.	Approved, Vet Approved
Mercaptopurine	The metabolism of Mercaptopurine can be decreased when combined with Olsalazine.	Approved
Mesalazine	Mesalazine may increase the nephrotoxic activities of Olsalazine.	Approved
Metamizole	Metamizole may increase the nephrotoxic activities of Olsalazine.	Withdrawn
Metformin	Olsalazine may increase the hypoglycemic activities of Metformin.	Approved
Methazolamide	The risk or severity of adverse effects can be increased when Olsalazine is combined with Methazolamide.	Approved
Methotrexate	The serum concentration of Methotrexate can be increased when it is combined with Olsalazine.	Approved
Methyclothiazide	The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Olsalazine.	Approved
Methylprednisolone	The risk or severity of adverse effects can be increased when Olsalazine is combined with Methylprednisolone.	Approved, Vet Approved
Metipranolol	Olsalazine may decrease the antihypertensive activities of Metipranolol.	Approved
Metolazone	The therapeutic efficacy of Metolazone can be decreased when used in combination with Olsalazine.	Approved
Metoprolol	Olsalazine may decrease the antihypertensive activities of Metoprolol.	Approved, Investigational
Metrizamide	Olsalazine may decrease the excretion rate of Metrizamide which could result in a higher serum level.	Approved
Mifepristone	Olsalazine may increase the hypoglycemic activities of Mifepristone.	Approved, Investigational
Miglitol	Olsalazine may increase the hypoglycemic activities of Miglitol.	Approved
Milrinone	The risk or severity of adverse effects can be increased when Milrinone is combined with Olsalazine.	Approved
Misoprostol	The therapeutic efficacy of Misoprostol can be decreased when used in combination with Olsalazine.	Approved
Mizoribine	Mizoribine may increase the nephrotoxic activities of Olsalazine.	Investigational
Moexipril	The risk or severity of adverse effects can be increased when Moexipril is combined with Olsalazine.	Approved
Mometasone	The risk or severity of adverse effects can be increased when Olsalazine is combined with Mometasone.	Approved, Vet Approved
Morniflumate	The risk or severity of adverse effects can be increased when Morniflumate is combined with Olsalazine.	Approved
Moxifloxacin	Olsalazine may increase the neuroexcitatory activities of Moxifloxacin.	Approved, Investigational
Mycophenolate mofetil	Mycophenolate mofetil may increase the nephrotoxic activities of Olsalazine.	Approved, Investigational
Mycophenolic acid	Mycophenolic acid may increase the nephrotoxic activities of Olsalazine.	Approved
Nabumetone	The risk or severity of adverse effects can be increased when Olsalazine is combined with Nabumetone.	Approved
Nadolol	Olsalazine may decrease the antihypertensive activities of Nadolol.	Approved
Nadroparin	The risk or severity of adverse effects can be increased when Olsalazine is combined with Nadroparin.	Approved
Nafamostat	Nafamostat may increase the nephrotoxic activities of Olsalazine.	Approved, Investigational
Naftifine	Naftifine may increase the nephrotoxic activities of Olsalazine.	Approved
Naftopidil	The risk or severity of adverse effects can be increased when Naftopidil is combined with Olsalazine.	Investigational
Nalidixic Acid	Olsalazine may increase the neuroexcitatory activities of Nalidixic Acid.	Approved
Naproxen	Naproxen may increase the nephrotoxic activities of Olsalazine.	Approved, Vet Approved
Nateglinide	Olsalazine may increase the hypoglycemic activities of Nateglinide.	Approved, Investigational
NCX 1022	The risk or severity of adverse effects can be increased when Olsalazine is combined with NCX 1022.	Investigational
NCX 4016	NCX 4016 may increase the nephrotoxic activities of Olsalazine.	Investigational
Neamine	Olsalazine may decrease the excretion rate of Neamine which could result in a higher serum level.	Experimental
Neomycin	Olsalazine may decrease the excretion rate of Neomycin which could result in a higher serum level.	Approved, Vet Approved
Nepafenac	Nepafenac may increase the nephrotoxic activities of Olsalazine.	Approved
Netilmicin	Olsalazine may decrease the excretion rate of Netilmicin which could result in a higher serum level.	Approved
Niflumic Acid	Niflumic Acid may increase the nephrotoxic activities of Olsalazine.	Approved
Nimesulide	Nimesulide may increase the nephrotoxic activities of Olsalazine.	Approved, Withdrawn
Nitroaspirin	The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Olsalazine.	Investigational
Norfloxacin	Olsalazine may increase the neuroexcitatory activities of Norfloxacin.	Approved
Octreotide	Olsalazine may increase the hypoglycemic activities of Octreotide.	Approved, Investigational
Ofloxacin	Olsalazine may increase the neuroexcitatory activities of Ofloxacin.	Approved
Oleandrin	The serum concentration of Anvirzel can be decreased when it is combined with Olsalazine.	Experimental
Oleoyl-estrone	The risk or severity of adverse effects can be increased when Olsalazine is combined with Oleoyl estrone.	Investigational
Olmesartan	The risk or severity of adverse effects can be increased when Olmesartan is combined with Olsalazine.	Approved, Investigational
Olopatadine	Olopatadine may increase the nephrotoxic activities of Olsalazine.	Approved
Omacetaxine mepesuccinate	The risk or severity of adverse effects can be increased when Olsalazine is combined with Omacetaxine mepesuccinate.	Approved
Omapatrilat	The risk or severity of adverse effects can be increased when Omapatrilat is combined with Olsalazine.	Investigational
Ouabain	The serum concentration of Ouabain can be decreased when it is combined with Olsalazine.	Approved
Oxaprozin	Oxaprozin may increase the nephrotoxic activities of Olsalazine.	Approved
Oxprenolol	Olsalazine may decrease the antihypertensive activities of Oxprenolol.	Approved
Oxyphenbutazone	Oxyphenbutazone may increase the nephrotoxic activities of Olsalazine.	Withdrawn
Ozagrel	The risk or severity of adverse effects can be increased when Olsalazine is combined with Kct 0809.	Investigational
Pamidronate	The risk or severity of adverse effects can be increased when Olsalazine is combined with Pamidronate.	Approved
Paramethasone	The risk or severity of adverse effects can be increased when Olsalazine is combined with Paramethasone.	Approved
Parecoxib	The risk or severity of adverse effects can be increased when Olsalazine is combined with Parecoxib.	Approved
Parnaparin	The risk or severity of adverse effects can be increased when Olsalazine is combined with Parnaparin.	Approved
Paromomycin	Olsalazine may decrease the excretion rate of Paromomycin which could result in a higher serum level.	Approved, Investigational
Pasireotide	Olsalazine may increase the hypoglycemic activities of Pasireotide.	Approved
Pazufloxacin	Olsalazine may increase the neuroexcitatory activities of Pazufloxacin.	Investigational
Pefloxacin	Olsalazine may increase the neuroexcitatory activities of Pefloxacin.	Approved
Penbutolol	Olsalazine may decrease the antihypertensive activities of Penbutolol.	Approved, Investigational
Pentamidine	Olsalazine may increase the hypoglycemic activities of Pentamidine.	Approved
Pentosan Polysulfate	Olsalazine may increase the anticoagulant activities of Pentosan Polysulfate.	Approved
Pentoxifylline	The risk or severity of adverse effects can be increased when Pentoxifylline is combined with Olsalazine.	Approved, Investigational
Perindopril	The risk or severity of adverse effects can be increased when Perindopril is combined with Olsalazine.	Approved
Phenindione	Olsalazine may increase the anticoagulant activities of Phenindione.	Approved
Phenprocoumon	Olsalazine may increase the anticoagulant activities of Phenprocoumon.	Approved
Phenylbutazone	Phenylbutazone may increase the nephrotoxic activities of Olsalazine.	Approved, Vet Approved
Pimecrolimus	Pimecrolimus may increase the nephrotoxic activities of Olsalazine.	Approved, Investigational
Pindolol	Olsalazine may decrease the antihypertensive activities of Pindolol.	Approved
Pioglitazone	Olsalazine may increase the hypoglycemic activities of Pioglitazone.	Approved, Investigational
Pirarubicin	Olsalazine may decrease the excretion rate of Pirarubicin which could result in a higher serum level.	Investigational
Piretanide	Olsalazine may decrease the diuretic activities of Piretanide.	Experimental
Pirfenidone	Pirfenidone may increase the nephrotoxic activities of Olsalazine.	Investigational
Piroxicam	Piroxicam may increase the nephrotoxic activities of Olsalazine.	Approved, Investigational
Plicamycin	Olsalazine may decrease the excretion rate of Plicamycin which could result in a higher serum level.	Approved, Withdrawn
Polythiazide	The therapeutic efficacy of Polythiazide can be decreased when used in combination with Olsalazine.	Approved
Practolol	Olsalazine may decrease the antihypertensive activities of Practolol.	Approved
Pralatrexate	The serum concentration of Pralatrexate can be increased when it is combined with Olsalazine.	Approved
Pramlintide	Olsalazine may increase the hypoglycemic activities of Pramlintide.	Approved, Investigational
Prasterone	The risk or severity of adverse effects can be increased when Olsalazine is combined with Prasterone.	Approved, Nutraceutical
Prasterone sulfate	The risk or severity of adverse effects can be increased when Olsalazine is combined with dehydroepiandrosterone sulfate.	Investigational
Prasugrel	The risk or severity of adverse effects can be increased when Prasugrel is combined with Olsalazine.	Approved
Prednicarbate	The risk or severity of adverse effects can be increased when Olsalazine is combined with Prednicarbate.	Approved
Prednisolone	The risk or severity of adverse effects can be increased when Olsalazine is combined with Prednisolone.	Approved, Vet Approved
Prednisone	The risk or severity of adverse effects can be increased when Olsalazine is combined with Prednisone.	Approved, Vet Approved
Pregnenolone	The risk or severity of adverse effects can be increased when Olsalazine is combined with Pregnenolone.	Experimental
Probenecid	The serum concentration of Olsalazine can be increased when it is combined with Probenecid.	Approved
Propacetamol	Propacetamol may increase the nephrotoxic activities of Olsalazine.	Approved
Propranolol	Olsalazine may decrease the antihypertensive activities of Propranolol.	Approved, Investigational
Prostaglandin B2	The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Olsalazine.	Experimental
Prostaglandin G2	The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Olsalazine.	Experimental
Protein S human	Olsalazine may increase the anticoagulant activities of Protein S human.	Approved
Prulifloxacin	Olsalazine may increase the neuroexcitatory activities of Prulifloxacin.	Investigational
PTC299	PTC299 may increase the nephrotoxic activities of Olsalazine.	Investigational
Puromycin	Olsalazine may decrease the excretion rate of Puromycin which could result in a higher serum level.	Experimental
Quinapril	The risk or severity of adverse effects can be increased when Quinapril is combined with Olsalazine.	Approved, Investigational
Quinethazone	The therapeutic efficacy of Quinethazone can be decreased when used in combination with Olsalazine.	Approved
Quinine	Olsalazine may increase the hypoglycemic activities of Quinine.	Approved
Ramatroban	The risk or severity of adverse effects can be increased when Ramatroban is combined with Olsalazine.	Investigational
Ramipril	The risk or severity of adverse effects can be increased when Ramipril is combined with Olsalazine.	Approved
Repaglinide	Olsalazine may increase the hypoglycemic activities of Repaglinide.	Approved, Investigational
Rescinnamine	The risk or severity of adverse effects can be increased when Rescinnamine is combined with Olsalazine.	Approved
Resveratrol	Resveratrol may increase the nephrotoxic activities of Olsalazine.	Experimental, Investigational
Reteplase	The risk or severity of adverse effects can be increased when Olsalazine is combined with Reteplase.	Approved
Reviparin	The risk or severity of adverse effects can be increased when Olsalazine is combined with Reviparin.	Approved
Ribostamycin	Olsalazine may decrease the excretion rate of Ribostamycin which could result in a higher serum level.	Approved
Ridogrel	The risk or severity of adverse effects can be increased when Ridogrel is combined with Olsalazine.	Approved
Rimexolone	The risk or severity of adverse effects can be increased when Olsalazine is combined with Rimexolone.	Approved
Risedronate	The risk or severity of adverse effects can be increased when Olsalazine is combined with Risedronate.	Approved, Investigational
Rivaroxaban	Olsalazine may increase the anticoagulant activities of Rivaroxaban.	Approved
Rofecoxib	The risk or severity of adverse effects can be increased when Olsalazine is combined with Rofecoxib.	Investigational, Withdrawn
Rosiglitazone	The risk or severity of adverse effects can be increased when Olsalazine is combined with Rosiglitazone.	Approved, Investigational
Rosoxacin	Olsalazine may increase the neuroexcitatory activities of Rosoxacin.	Approved
Sacubitril	The risk or severity of adverse effects can be increased when Sacubitril is combined with Olsalazine.	Approved
Salicylamide	Salicylamide may increase the nephrotoxic activities of Olsalazine.	Approved
Salicylic acid	Salicylic acid may increase the nephrotoxic activities of Olsalazine.	Approved, Vet Approved
Salsalate	Salsalate may increase the nephrotoxic activities of Olsalazine.	Approved
Saprisartan	The risk or severity of adverse effects can be increased when Saprisartan is combined with Olsalazine.	Experimental
Saxagliptin	Olsalazine may increase the hypoglycemic activities of Saxagliptin.	Approved
Selexipag	The risk or severity of adverse effects can be increased when Olsalazine is combined with Selexipag.	Approved
Sevoflurane	The risk or severity of adverse effects can be increased when Sevoflurane is combined with Olsalazine.	Approved, Vet Approved
Sisomicin	Olsalazine may decrease the excretion rate of Sisomicin which could result in a higher serum level.	Investigational
Sitagliptin	Olsalazine may increase the hypoglycemic activities of Sitagliptin.	Approved, Investigational
Sotalol	Olsalazine may decrease the antihypertensive activities of Sotalol.	Approved
SP1049C	Olsalazine may decrease the excretion rate of SP1049C which could result in a higher serum level.	Investigational
Sparfloxacin	Olsalazine may increase the neuroexcitatory activities of Sparfloxacin.	Approved
Spectinomycin	Olsalazine may decrease the excretion rate of Spectinomycin which could result in a higher serum level.	Approved, Vet Approved
Spirapril	The risk or severity of adverse effects can be increased when Spirapril is combined with Olsalazine.	Approved
Spironolactone	Olsalazine may decrease the antihypertensive activities of Spironolactone.	Approved
SRT501	SRT501 may increase the nephrotoxic activities of Olsalazine.	Investigational
Streptokinase	The risk or severity of adverse effects can be increased when Olsalazine is combined with Streptokinase.	Approved
Streptomycin	Olsalazine may decrease the excretion rate of Streptomycin which could result in a higher serum level.	Approved, Vet Approved
Streptozocin	Olsalazine may decrease the excretion rate of Streptozocin which could result in a higher serum level.	Approved
Sulfadiazine	Olsalazine may increase the hypoglycemic activities of Sulfadiazine.	Approved, Vet Approved
Sulfamethoxazole	Olsalazine may increase the hypoglycemic activities of Sulfamethoxazole.	Approved
Sulfasalazine	Sulfasalazine may increase the nephrotoxic activities of Olsalazine.	Approved
Sulfisoxazole	Olsalazine may increase the hypoglycemic activities of Sulfisoxazole.	Approved, Vet Approved
Sulindac	Sulindac may increase the nephrotoxic activities of Olsalazine.	Approved
Sulodexide	Olsalazine may increase the anticoagulant activities of Sulodexide.	Approved, Investigational
Sulprostone	The therapeutic efficacy of Sulprostone can be decreased when used in combination with Olsalazine.	Investigational
Sunitinib	Olsalazine may increase the hypoglycemic activities of Sunitinib.	Approved, Investigational
Suprofen	Suprofen may increase the nephrotoxic activities of Olsalazine.	Approved, Withdrawn
Tacrolimus	Olsalazine may increase the nephrotoxic activities of Tacrolimus.	Approved, Investigational
Tafluprost	The therapeutic efficacy of Tafluprost can be decreased when used in combination with Olsalazine.	Approved
Talniflumate	The risk or severity of adverse effects can be increased when Talniflumate is combined with Olsalazine.	Approved
Tasosartan	The risk or severity of adverse effects can be increased when Tasosartan is combined with Olsalazine.	Approved
Technetium Tc-99m medronate	The risk or severity of adverse effects can be increased when Olsalazine is combined with Technetium Tc-99m Medronate.	Approved
Telmisartan	The risk or severity of adverse effects can be increased when Telmisartan is combined with Olsalazine.	Approved, Investigational
Temafloxacin	Olsalazine may increase the neuroexcitatory activities of Temafloxacin.	Withdrawn
Temocapril	The risk or severity of adverse effects can be increased when Temocapril is combined with Olsalazine.	Experimental, Investigational
Tenecteplase	The risk or severity of adverse effects can be increased when Olsalazine is combined with Tenecteplase.	Approved
Tenofovir disoproxil	The risk or severity of adverse effects can be increased when Olsalazine is combined with Tenofovir.	Approved, Investigational
Tenoxicam	Tenoxicam may increase the nephrotoxic activities of Olsalazine.	Approved
Teriflunomide	Teriflunomide may increase the nephrotoxic activities of Olsalazine.	Approved
Tesmilifene	The risk or severity of adverse effects can be increased when Tesmilifene is combined with Olsalazine.	Investigational
Tiaprofenic acid	Tiaprofenic acid may increase the nephrotoxic activities of Olsalazine.	Approved
Ticagrelor	The risk or severity of adverse effects can be increased when Olsalazine is combined with Ticagrelor.	Approved
Ticlopidine	The risk or severity of adverse effects can be increased when Ticlopidine is combined with Olsalazine.	Approved
Tiludronic acid	The risk or severity of adverse effects can be increased when Olsalazine is combined with Tiludronate.	Approved, Vet Approved
Timolol	Olsalazine may decrease the antihypertensive activities of Timolol.	Approved
Tinoridine	Tinoridine may increase the nephrotoxic activities of Olsalazine.	Investigational
Tinzaparin	The risk or severity of adverse effects can be increased when Olsalazine is combined with Tinzaparin.	Approved
Tioguanine	The metabolism of Tioguanine can be decreased when combined with Olsalazine.	Approved
Tirofiban	The risk or severity of adverse effects can be increased when Tirofiban is combined with Olsalazine.	Approved
Tixocortol	The risk or severity of adverse effects can be increased when Olsalazine is combined with Tixocortol.	Approved
Tobramycin	Olsalazine may decrease the excretion rate of Tobramycin which could result in a higher serum level.	Approved, Investigational
Tolazamide	Olsalazine may increase the hypoglycemic activities of Tolazamide.	Approved
Tolbutamide	Olsalazine may increase the hypoglycemic activities of Tolbutamide.	Approved
Tolfenamic Acid	Tolfenamic Acid may increase the nephrotoxic activities of Olsalazine.	Approved
Tolmetin	Tolmetin may increase the nephrotoxic activities of Olsalazine.	Approved
Torasemide	Olsalazine may decrease the diuretic activities of Torasemide.	Approved
Trandolapril	The risk or severity of adverse effects can be increased when Trandolapril is combined with Olsalazine.	Approved
Tranilast	Tranilast may increase the nephrotoxic activities of Olsalazine.	Approved, Investigational
Trapidil	The risk or severity of adverse effects can be increased when Trapidil is combined with Olsalazine.	Approved
Travoprost	The therapeutic efficacy of Travoprost can be decreased when used in combination with Olsalazine.	Approved
Treprostinil	The risk or severity of adverse effects can be increased when Treprostinil is combined with Olsalazine.	Approved, Investigational
Triamcinolone	The risk or severity of adverse effects can be increased when Olsalazine is combined with Triamcinolone.	Approved, Vet Approved
Triamterene	Olsalazine may decrease the antihypertensive activities of Triamterene.	Approved
Trichlormethiazide	The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Olsalazine.	Approved, Vet Approved
Triflusal	The risk or severity of adverse effects can be increased when Triflusal is combined with Olsalazine.	Approved
Trovafloxacin	Olsalazine may increase the neuroexcitatory activities of Trovafloxacin.	Approved, Withdrawn
Unoprostone	The therapeutic efficacy of Unoprostone can be decreased when used in combination with Olsalazine.	Approved
Urokinase	The risk or severity of adverse effects can be increased when Olsalazine is combined with Urokinase.	Approved, Investigational, Withdrawn
Valdecoxib	The risk or severity of adverse effects can be increased when Olsalazine is combined with Valdecoxib.	Investigational, Withdrawn
Valproic Acid	The serum concentration of Valproic Acid can be increased when it is combined with Olsalazine.	Approved, Investigational
Valrubicin	Olsalazine may decrease the excretion rate of Valrubicin which could result in a higher serum level.	Approved
Valsartan	The risk or severity of adverse effects can be increased when Valsartan is combined with Olsalazine.	Approved, Investigational
Vancomycin	The serum concentration of Vancomycin can be increased when it is combined with Olsalazine.	Approved
Verapamil	Verapamil may increase the anticoagulant activities of Olsalazine.	Approved
Vorapaxar	The risk or severity of adverse effects can be increased when Vorapaxar is combined with Olsalazine.	Approved
Warfarin	Olsalazine may increase the anticoagulant activities of Warfarin.	Approved
Ximelagatran	Olsalazine may increase the anticoagulant activities of Ximelagatran.	Approved, Investigational, Withdrawn
Zaltoprofen	Zaltoprofen may increase the nephrotoxic activities of Olsalazine.	Approved
Zileuton	Zileuton may increase the nephrotoxic activities of Olsalazine.	Approved, Investigational, Withdrawn
Zoledronic acid	The risk or severity of adverse effects can be increased when Olsalazine is combined with Zoledronic acid.	Approved
Zomepirac	Zomepirac may increase the nephrotoxic activities of Olsalazine.	Withdrawn
Zorubicin	Olsalazine may decrease the excretion rate of Zorubicin which could result in a higher serum level.	Experimental

Food Interactions

Not Available

References

Synthesis Reference

Not Available

General References

Not Available

External Links

Resource	Link
Human Metabolome Database (HMDB)	HMDB15380
KEGG Drug	D00727
KEGG Compound	C07323
PubChem Compound	6003770
PubChem Substance	46506356
ChemSpider	10642377
ChEMBL	CHEMBL425
PharmGKB	PA450700
Drug Product Database	1226
RxList	http://www.rxlist.com/cgi/cgi/generic/olsal.htm
Drugs.com	http://www.drugs.com/cdi/olsalazine.html
Wikipedia	Olsalazine

ATC Codes

A07EC03 — Olsalazine

AHFS Codes

56:36.00

PDB Entries

Not Available

FDA label

Not Available

MSDS

Not Available

Clinical Trials

Phase	Status	Purpose	Conditions	Count
2	Completed	Treatment	Ankylosing Spondylitis (AS)	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Dosage forms

Form	Route	Strength
Capsule	Oral	250 mg
Capsule, gelatin coated	Oral	250 mg/1

Prices

Unit description	Cost	Unit
Dipentum 250 mg capsule	1.8USD	capsule

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Not Available

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	Sodium salt decomposes at 240 °C	Not Available
logP	2.3	Not Available
Caco2 permeability	-6.96	ADME Research, USCD

Predicted Properties

Property	Value	Source
Water Solubility	0.0781 mg/mL	ALOGPS
logP	2.77	ALOGPS
logP	4.39	ChemAxon
logS	-3.6	ALOGPS
pKa (Strongest Acidic)	2.93	ChemAxon
pKa (Strongest Basic)	-0.019	ChemAxon
Physiological Charge	-2	ChemAxon
Hydrogen Acceptor Count	8	ChemAxon
Hydrogen Donor Count	4	ChemAxon
Polar Surface Area	139.78 Å²	ChemAxon
Rotatable Bond Count	4	ChemAxon
Refractivity	78.85 m³·mol^-1	ChemAxon
Polarizability	28.61 Å³	ChemAxon
Number of Rings	2	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.8502
Blood Brain Barrier	+	0.6279
Caco-2 permeable	-	0.6449
P-glycoprotein substrate	Non-substrate	0.7433
P-glycoprotein inhibitor I	Non-inhibitor	0.8628
P-glycoprotein inhibitor II	Non-inhibitor	0.9525
Renal organic cation transporter	Non-inhibitor	0.8844
CYP450 2C9 substrate	Non-substrate	0.7774
CYP450 2D6 substrate	Non-substrate	0.8748
CYP450 3A4 substrate	Non-substrate	0.6636
CYP450 1A2 substrate	Non-inhibitor	0.8006
CYP450 2C9 inhibitor	Non-inhibitor	0.7804
CYP450 2D6 inhibitor	Non-inhibitor	0.9047
CYP450 2C19 inhibitor	Non-inhibitor	0.8638
CYP450 3A4 inhibitor	Non-inhibitor	0.8309
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.8912
Ames test	Non AMES toxic	0.9132
Carcinogenicity	Non-carcinogens	0.5546
Biodegradation	Not ready biodegradable	0.8701
Rat acute toxicity	1.4882 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9506
hERG inhibition (predictor II)	Non-inhibitor	0.9453

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum Type	Description	Splash Key
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Negative	Not Available

Taxonomy

Description

This compound belongs to the class of chemical entities known as azobenzenes. These are organonitrogen aromatic compounds that contain a central azo group, where each nitrogen atom is conjugated to a benzene ring.

Kingdom

Chemical entities

Super Class

Organic compounds

Class

Organoheterocyclic compounds

Sub Class

Azobenzenes

Direct Parent

Azobenzenes

Alternative Parents

Salicylic acids / Benzoic acids / Benzoyl derivatives / 1-hydroxy-2-unsubstituted benzenoids / Dicarboxylic acids and derivatives / Vinylogous acids / Azo compounds / Propargyl-type 1,3-dipolar organic compounds / Carboxylic acids / Organopnictogen compounds

Substituents

Azobenzene / Hydroxybenzoic acid / Salicylic acid or derivatives / Salicylic acid / Benzoic acid or derivatives / Benzoic acid / Benzoyl / 1-hydroxy-2-unsubstituted benzenoid / Phenol / Monocyclic benzene moiety

Molecular Framework

Aromatic homomonocyclic compounds

External Descriptors

Not Available

Targets

Details

1. Thiopurine S-methyltransferase

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: inhibitor

General Function:: Thiopurine s-methyltransferase activity
Specific Function:: Catalyzes the S-methylation of thiopurine drugs such as 6-mercaptopurine.
Gene Name:: TPMT
Uniprot ID:: P51580
Molecular Weight:: 28180.09 Da

References

Lewis LD, Benin A, Szumlanski CL, Otterness DM, Lennard L, Weinshilboum RM, Nierenberg DW: Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction. Clin Pharmacol Ther. 1997 Oct;62(4):464-75. [PubMed:9357398 ]
Lennard L: TPMT in the treatment of Crohn's disease with azathioprine. Gut. 2002 Aug;51(2):143-6. [PubMed:12117866 ]
Lennard L: Clinical implications of thiopurine methyltransferase--optimization of drug dosage and potential drug interactions. Ther Drug Monit. 1998 Oct;20(5):527-31. [PubMed:9780130 ]
Shipkova M, Niedmann PD, Armstrong VW, Oellerich M, Wieland E: Determination of thiopurine methyltransferase activity in isolated human erythrocytes does not reflect putative in vivo enzyme inhibition by sulfasalazine. Clin Chem. 2004 Feb;50(2):438-41. [PubMed:14752016 ]

Details

2. Interferon gamma

Kind: Protein
Organism: Human
Pharmacological action: yes

General Function:: Interferon-gamma receptor binding
Specific Function:: Produced by lymphocytes activated by specific antigens or mitogens. IFN-gamma, in addition to having antiviral activity, has important immunoregulatory functions. It is a potent activator of macrophages, it has antiproliferative effects on transformed cells and it can potentiate the antiviral and antitumor effects of the type I interferons.
Gene Name:: IFNG
Uniprot ID:: P01579
Molecular Weight:: 19348.165 Da

References

Egan LJ, Sandborn WJ: Inhibition of nuclear factor kappaB by sulfasalazine: a new target for inflammatory bowel disease therapy? Gastroenterology. 1998 Nov;115(5):1295-6. [PubMed:9797390 ]
Ito R, Shin-Ya M, Kishida T, Urano A, Takada R, Sakagami J, Imanishi J, Kita M, Ueda Y, Iwakura Y, Kataoka K, Okanoue T, Mazda O: Interferon-gamma is causatively involved in experimental inflammatory bowel disease in mice. Clin Exp Immunol. 2006 Nov;146(2):330-8. [PubMed:17034586 ]

Drug created on March 30, 2007 06:25 / Updated on July 18, 2017 16:57

Get DrugBank to go!

Structure for DB01250 (Olsalazine)

Targets

References

References